Cary Street Partners Investment Advisory’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-183	Closed	-$21.2K	–	1883
2023 Q3	$21.2K	Hold	183	–	–	﹤0.01%	1098
2023 Q2	$18.8K	Hold	183	–	–	﹤0.01%	1061
2023 Q1	$20K	Sell	183 -7,982	-98%	-$882K	﹤0.01%	974
2022 Q4	$929K	Sell	8,165 -789	-9%	-$65.5K	0.07%	242
2022 Q3	$554K	Sell	8,954 -122	-1%	-$8.53K	0.05%	296
2022 Q2	$724K	Buy	+9,076	New	+$859K	0.06%	250

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cary Street Partners Investment Advisory's HZNP Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 183 shares — an estimated $21.2K sold.

Cary Street Partners Investment Advisory first reported a position in HZNP in Q2 2022 and held it in 6 quarters. The position peaked at $929K in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Cary Street Partners Investment Advisory reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 183 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $21.2K.
Cary Street Partners Investment Advisory first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and held it in 6 quarters.
Cary Street Partners Investment Advisory's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $929K in Q4 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.